Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinically significant macular edema
* Possibility of performing macular OCT
* Consent of patient for inclusion in the study
Exclusion Criteria
* Necessity of surgical intervention
* Rejection of the remaining in the study by patient
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Isfahan Ophthalmology Research Center
NETWORK
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MUI - clinical - 185290
Identifier Type: -
Identifier Source: org_study_id